|Printable version||E-mail this to a friend|
ESMA updates MAR guidelines on market soundings
The European Securities and Markets Authority (ESMA) yesterday re-issued the official translations of its final guidelines clarifying the implementation of the Market Abuse Regulation (MAR) for persons receiving market soundings.
Following a linguistic issue in the Polish translation, all 22 language versions are being re-published today which moves its legal application date to 10 January 2017. Today’s publication triggers the period of two months within which national competent authorities subject to these guidelines have to notify ESMA whether or not they intend to comply with the guidelines. However, these updates do not concern the substance of the other guidelines which remains unchanged.
The new market abuse regime strengthens the existing market abuse framework by extending its scope to new markets, platforms and trading behaviors. It contains prohibitions for insider dealing and market manipulation, and provisions to prevent and detect these.
MAR GUIDELINES - PERSONS RECEIVING MARKET SOUNDINGS
2016-1477_MAR_GUIDELINES_-_MARKET_SOUNDINGS.PDF (278.79 KB)
Latest News from
EU invests €444m in key energy infrastructure20/02/2017 16:05:00
The 18 selected electricity, smart grids and gas projects will contribute to achieving the Energy Union's goals by connecting European energy networks, increasing security of energy supply, and contributing to the sustainable development by integrating renewable energy sources across the EU.
Ombudsman: System of unpaid trainees in EU foreign delegations should end20/02/2017 14:10:00
Following a complaint from a young EU trainee, the European Ombudsman, Emily O'Reilly, has recommended that the European External Action Service pay all of its trainees an appropriate allowance to allow greater access for young people of all backgrounds.
First monoclonal antibody in a veterinary medicine recommended for a marketing authorisation20/02/2017 13:20:00
This is a solution for injection containing the new active substance lokivetmab, the first monoclonal antibody in a veterinary medicine in the EU. It is intended for the treatment of dogs with atopic dermatitis, a common allergic skin disease.
Consultation on revised policy on access to documents20/02/2017 12:10:00
The European Medicines Agency (EMA) has launched a public consultation on the proposed revision to its policy on access to documents.